What is the mechanism of action of rogocekib?

Rogocekib inhibits CLK, modulating RNA splicing to disrupt cancer cell survival.

What was the patient population in the trial?

78.6% were over 65, and 57.1% had three or more prior therapies, indicating a heavily pretreated group.

What is the next development step?

Expansion cohorts are ongoing under a revised protocol finalized in December 2025.

How will the data be presented at EHA?

As a poster presentation on June 13, 2026, from 18:45–19:45 CEST.

What is the dosing regimen for rogocekib?

Oral administration once or twice weekly, with doses ranging from 20mg to 140mg.

AI News NQ Analysis

Announcement of Rogocekib Dose-Escalation Cohort Data Presentation at the 2026 European Hematology Association (EHA)

NQ Score 89/100

N1 Content Completeness 9

AI Summary (NQ-processed)

Chordia Therapeutics has announced data from the Phase 1/2 trial (CTX-712-CL-02) of rogocekib (CTX-712), a CLK inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The trial demonstrated a manageable safety profile and preliminary anti-tumor activity as monotherapy in heavily pretreated patients. Results will be presented at EHA 2026.

AI Analysis

Frequently Asked Questions

Q: What is the mechanism of action of rogocekib?: A: Rogocekib inhibits CLK, modulating RNA splicing to disrupt cancer cell survival.
Q: What was the patient population in the trial?: A: 78.6% were over 65, and 57.1% had three or more prior therapies, indicating a heavily pretreated group.
Q: What is the next development step?: A: Expansion cohorts are ongoing under a revised protocol finalized in December 2025.
Q: How will the data be presented at EHA?: A: As a poster presentation on June 13, 2026, from 18:45–19:45 CEST.
Q: What is the dosing regimen for rogocekib?: A: Oral administration once or twice weekly, with doses ranging from 20mg to 140mg.